Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 15/20 | 0.37 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.35 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.35 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.35 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4890256 | 0.89 | NAMPT (0.40) | NAMPT | |
| SCHEMBL2940400 | 0.83 | IGF1R (0.35) | MEN1KMT2A | |
| SCHEMBL4884585 | 0.80 | IGF1R (0.36) | NAMPTMEN1KMT2A | |
| SCHEMBL2936439 | 0.79 | IGF1R (0.32) | MEN1KMT2A | |
| SCHEMBL3730717 | 0.77 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL4884670 | 0.77 | IGF1R (0.34) | MEN1KMT2A | |
| SCHEMBL3727464 | 0.77 | IGF1R (0.41) | — | |
| SCHEMBL4888699 | 0.77 | MAPT (0.34) | — | |
| SCHEMBL5487628 | 0.76 | — | — | |
| Trifluoroacetic Acid SCHEMBL4883973 | 0.76 | IGF1R (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021029-A1 | Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-01-24 | — | — | US | disclosed |
| EP-1621535-A1 | Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | Aventis Pharma S.A. (FR) | 2006-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021029-A1 | Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | PRKAR2B, PRKG2, PRKG1 | NAMPT 2443/4885ABCC9 1293/4885ABCC8 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.